Your search returned 653 matches
Records 11 through 21
Testimony on Rosiglitazone (Avandia) Safety (HRG Publication #1913)
Rosiglitazone (Avandia) compares unfavorably to Pioglitazone (Actos) and should be removed from the market.
[Created on: 08/17/2010]
[Created on: 07/15/2010]
Comments on Direct-to-Consumer Drug Advertising (HRG #1910)
Public Citizen proposes stricter regulations concerning direct-to-consumer drug advertising.
[Created on: 06/28/2010]
Letter Urging FDA to Halt Rosiglitazone (Avandia) Trial (HRG Publication #1908)
We urge the FDA to halt an international diabetes trial that would put patients at unnecessary risk.
[Created on: 05/10/2010]
Testimony of Sidney M. Wolfe, M.D. Director, Health Research Group at Public Citizen Before House Agriculture-FDA Appropriations Subcommittee Hearing on Rosiglitazone (Avandia) (HRG Publication #1907)
Dr. Wolfe explains why the TIDE study must be stopped immediately, and pushes the FDA to ban rosiglitazone (Avandia).
[Created on: 04/28/2010]
Testimony on the Cancer Risk of Calcineurin Inhibitor Skin Medications Tacrolimus (Protopic) and Pimecrolimus (Elidel) (HRG Publication #1904
Sidney Wolfe, M.D. testified about the lymphoma risk posed to children by the ezcema medications tacrolinus (Protopic) and pimecrolimus (Elidel).
[Created on: 03/22/2010]
Letter to FDA Praising Food Safety Cautiousness, Attacking Drug Safety Recklessness (HRG Publication #1903)
In contrast to becoming more active and cautious in enhancing food safety by removing potentially dangerous products before they have caused harm, several FDA decisions in the past year regarding prescription drugs can only be described as reckless.
[Created on: 03/08/2010]
Article in Health Matrix: Survey of State Medical and Osteopathy Board Disciplinary Web Sites in 2006
(HRG Publication #1902)
We sought to describe doctor disciplinary information provided on the web sites of state medical and osteopathic boards. Information collected included state board, hospital and federal government actions, as well as malpractice judgments and settlements and conviction information.
[Created on: 02/04/2010]
Open Letter to Executive Director of the Accreditation Council of Graduate Medical Education (ACGME) (HRG Publication #1901)
We encourage the ACGME to adopt the IOM's resident work hour limit recommendations.
[Created on: 01/28/2010]
Petition to Ban Fibromyalgia Drug Milnacipran (Savella) (HRG Publication #1900)
Milnacipran (Savella) has highly questionable clinical efficacy and has been associated with a large number of potentially serious adverse reactions including hypertension, increased heart rate and an increased incidence of suicidal ideation.
[Created on: 01/19/2010]
|<<Previous 10||Next 10>>|